Innovation and Technology in Diagnostics: from Detection to Anticipation

Archana Devadiga
Yashraj Biotechnology Ltd., India

Dipti Dama
Yashraj Biotechnology Ltd., India

Nandana Sadanandan
Yashraj Biotechnology Ltd., India

The diagnostics industry is entering a defining decade. For years, success in diagnostics was measured by accuracy, turnaround time, and the ability to confirm disease with confidence. Those pillars still matter. But the conversation has shifted from 'sick-care' (testing to confirm a disease) to 'well-care'—intercepting a disease before clinical symptoms manifest. Diagnostics is no longer expected only to identify disease after symptoms appear; it is increasingly expected to predict risk earlier, compress turnaround times through proactive analysis, support clinical decision-making faster, and bring testing closer to where patients actually are.

This transition is being driven by the convergence of three powerful forces: genomics, artificial intelligence (AI), and decentralized testing. Together, they are reshaping diagnostics from a reactive service into a strategic engine of modern healthcare. The implications are significant not only for clinicians and laboratories, but also for manufacturers, policymakers, and health systems trying to improve outcomes at scale.

For India, the opportunity is especially compelling1. The country combines a vast and diverse population, rapidly formalizing digital health infrastructure, strong scientific capability, and an increasingly innovation-oriented diagnostics ecosystem. That combination creates a rare advantage: India is not merely positioned to adopt global diagnostic technologies, but to help define the next phase of them.

Molecular diagnostics: decoding disease at the DNA level

One of the most important shifts in diagnostics is the growing relevance of genomics and personalized medicine in routine care. Genomic technologies have moved far beyond academic research and are now influencing disease risk assessment, rare disease diagnosis, therapy selection, and preventive screening1. The larger point is clear: diagnostics is moving away from 'one-size-fits-all' medicine toward highly targeted therapies, personalized medicine, and pharmacogenomics—matching the right drug to the right genetic profile.

Historically, standard genetic mapping was heavily biased toward Western, non-Indian genomic data, creating a massive diagnostic blindspot for non-Caucasian populations and limiting the transferability of risk markers. To address this, India focused on localizing its genomic database through the government-funded Genome India Project. The project successfully sequenced the whole genomes of 10,000 individuals across 99 distinct Indian communities, building a critical national genomic resource.

The business and clinical implications are substantial1. Population-specific genomic references improve biomarker interpretation and support the

development of cost-effective, population-specific diagnostics for genetic disorders that affect an estimated 70 million Indians. Simultaneously, healthtech startups are blending these molecular diagnostics with advanced imaging to launch longevity and preventive clinics nationwide.

The technological frontier of molecular diagnostics is highlighted by the rise of Multi-Cancer Early Detection (MCED) tests, alongside innovations like Next-Generation Sequencing (NGS), CRISPR-based diagnostics, and Liquid Biopsies (which detect cancer via a simple blood draw rather than painful physical tissue biopsies).

Real-world breakthroughs in MCED

- **GRAIL's Galleri Test:** Uses NGS and AI-driven methylation analysis to screen for over 50 types of cancer from a single blood draw before symptoms appear.
- **Guardant Health's Shield:** A blood-based test advancing non-invasive colorectal and multi-cancer screening.

Clinical trade-offs of advanced genomics

- **The Clinical Pros:** MCED tests offer early interception for aggressive cancers (like pancreatic or ovarian) that lack standard screening protocols. They boost patient compliance because routine blood draws are preferred over invasive imaging. Furthermore, they deliver extreme specificity (exceeding 99%), making false-positive alarms incredibly rare.
- **The Clinical Cons:** While highly specific, sensitivity for early Stage I cancers can still hover around 50% depending on the tumor type. Additionally, these tests remain expensive, and universal insurance coverage remains a primary bottleneck. There is also an increasing risk of over-diagnosis—finding indolent, non-threatening micro-anomalies that trigger profound patient anxiety and unnecessary diagnostic pathways.

Scientific sophistication matters, but the future of innovation will depend on how intelligently companies convert genomic insight into clinically usable, affordable, and scalable tests.

Artificial intelligence is entering mainstream diagnostics

If genomics expands what can be known, AI expands what can be done with that knowledge. AI has officially transitioned from experimental lab models into heavy clinical deployment. By the end of 2025, the U.S. FDA had authorized more than 1,400 AI-enabled medical devices, with a record-shattering 295 clearances added in 2025 alone. Radiology remains the most visible leader, accounting for roughly 75% of approvals (imaging, CT scan triage, chest X-rays), followed by cardiology at ~9% (ECG interpretation, echocardiogram analysis), and neurology & pathology at ~5% (stroke detection, digital cancer biopsy reviews).

The significance of AI in diagnostics is not that machines replace clinical judgment; global regulatory bodies explicitly recognize these tools as decision-support systems that keep a 'human-in-the-loop'. In overloaded healthcare systems, AI serves as a force multiplier, helping professionals prioritize urgent cases, eliminate fatigue-induced human errors, and optimize hospital logistics and staff scheduling.

AI's measurable impact in healthcare

1. **Diagnostics (Computer Vision & Machine Learning):** AI spots early signs of disease with incredible speed. In a 2020 multicenter study involving more than 270,000 patient records across 461 U.S. hospitals, a machine-learning algorithm analyzed routinely collected vital signs in EHRs to predict severe sepsis up to 48 hours before clinical onset, outperforming conventional screening methods and giving clinicians a valuable window for life-saving interventions.
2. **Operations & Administration:** Platforms like IMT Care simplify healthcare administration and insurance services. By automating claims tracking, network hospital location, and paperwork through a single mobile application, digital health platforms reduce administrative friction and improve processing times, allowing professionals to focus on care.
3. **Personalized Care:** Projects like the NHS Greater Glasgow and Clyde DYNAMIC-AI project in Scotland use predictive algorithms to analyze medical histories, medications, and clinical records. The system generates a personalized risk score predicting a chronic disease patient's likelihood of health deterioration over 12 months, allowing multidisciplinary teams to deliver timely interventions before conditions worsen.
4. **Global & Indian regulatory evolution**

As AI software becomes dynamic, global regulatory frameworks are moving away from ad-hoc approvals toward structured, lifecycle-based governance designed for Software as a Medical Device (SaMD). In August 2025, the U.S. FDA, Health Canada, and the UK's MHRA jointly released guidelines for Predetermined Change Control Plans

(PCCPs). This allows developers to outline future machine-learning algorithmic updates in advance, avoiding the need for a brand-new clearance every time the model learns from new data. Meanwhile, Europe utilizes the stringent In Vitro Diagnostic Regulation (IVDR) and the EU AI Act, applying a risk-based approach that demands robust, localized validation data for high-risk profiles.

India has radically formalized its digital health framework2. AI-driven diagnostic tools are regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Medical Devices Rules (MDR), 20172. Software that independently diagnoses or monitors conditions is classified as SaMD across a four-tier risk framework. Recent 2025–2026 milestones include mandatory Class C regulatory oversight for AI-based cancer detection, the introduction of the Algorithm Change Protocol (ACP) guidance document, and the launch of the Strategy for AI in Healthcare in India (SAHI) alongside the BODH validation platform developed with IIT Kanpur. Furthermore, the Ayushman Bharat Digital Mission (ABDM) now provides sandbox environments allowing healthtech startups to securely link AI screening software directly with automated Electronic Health Records.

Real-world deployment examples

1. **AI Stroke Platforms:** Automatically analyze CT scans in real time to detect large vessel occlusions and instantly alert emergency teams.
2. **IDx-DR:** An autonomous AI diagnostic system analyzing retinal photographs to detect diabetic retinopathy in primary care settings without an ophthalmologist on site.
3. **Caption AI:** Employs real-time AI to guide non-specialized nurses to capture diagnostic-quality cardiac ultrasounds.
4. **National Health Programs:** Frontline workers in rural Indian districts use algorithms developed by Qure.ai to screen chest X-rays for Tuberculosis instantly2. India's eSanjeevani telemedicine platform has leveraged AI-driven differential diagnosis across over 280 million public consultations.
5. **Early Alzheimer's Screening:** In early 2026, Mahajan Imaging deployed India's first AI-powered workflow combining blood-based biomarkers (pTau/Aβ assays) with MRI imaging via mobile phlebotomy units.

Point-of-Care Testing (POCT) is changing access

The decentralization of the laboratory is a defining trend of the mid-2020s. The laboratory is expanding outward into clinics, pharmacies, ambulances, workplaces, and homes, converting them into mini-clinics using multiplex testing and connected cloud ecosystems.

In India, the explosion of the Direct-to-Consumer (D2C) home-collection model completely transformed the country's unorganized lab market. Diagnostic apps have digitized the 'front-door experience'—making WhatsApp-based booking, UPI automated payments, and barcode-tracked cold chains standard practice. This shift is powered by innovations like microfluidics, lab-on-a-chip technologies, wearable continuous biosensors, and smartphone-connected diagnostic readers. Real-world examples include BioMérieux's BioFire Spotfire for near-patient respiratory PCR molecular testing in under 20 minutes and the Ozelle EHBT-50 Mini-Lab, a cartridge-based device delivering a 7-part CBC, biochemistry, and immunoassay markers from 30 microliters of blood in 6 minutes using AI cell imaging.

The next competitive edge is integration

The most important innovation trend in diagnostics may not be a single technology at all; it is the integration of technologies into a coherent diagnostic ecosystem1. Genomics generates deep biological insight, AI turns complex data into interpretable patterns, and point-of-care systems bring results closer to the patient1. The real value emerges when these capabilities work together rather than in isolation. Prominent digital health enablers in India include HealthifyMe, which employs an AI coaching system ('Ria') leveraging 25 million data points for personalized lifestyle modification, and Tata 1mg, India's largest integrated digital health platform achieving a 22% growth in service speed while streamlining corporate check-ups.

A strategic paradigm for global healthcare

The diagnostics sector has reached a structural inflection point. It is moving from post-symptomatic detection to preventative anticipation, from operational fragmentation to unified clinical ecosystems, and from isolated instruments to intelligent, cloud-integrated diagnostic platforms. For India, this represents far more than an engineering milestone; it is a profound strategic opportunity. By engineering solutions tailored to complex care pathways, rigid pricing realities, and diverse demographic profiles, the Indian diagnostics ecosystem is no longer merely reacting to global medical breakthroughs—it is laying down the framework to pioneer them.